GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects
Phase 1
Completed
- Conditions
- Anaemia
- Interventions
- Drug: GSK1278863A PlaceboDrug: GSK1278863A
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT02348372
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia
A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Budesonide/FormoterolDrug: Triple FF/UMEC/VIDrug: Placebo to match FF/UMEC/VIDrug: Placebo to match Budesonide/Formoterol combinationDrug: Albuterol/salbutamol
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1811
- Registration Number
- NCT02345161
- Locations
- 🇺🇦
GSK Investigational Site, Vinnytsia, Ukraine
Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT02345174
- Locations
- 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands
fMRI Study to Investigate Hemodynamic Changes in Brain Resulting From Supplementation of Bacopa Monnieri Extract and Multiple Micronutrient Supplementation.
Not Applicable
Completed
- Conditions
- Growth and Development
- Interventions
- Dietary Supplement: Non-fortified isocaloric beverage powderDietary Supplement: Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT02345187
- Locations
- 🇮🇳
GSK Investigational Site, New Delhi, India
This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age
Completed
- Conditions
- Hepatitis B
- Interventions
- Other: Data collection
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 161429
- Registration Number
- NCT02324218
Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Respiratory Disorders
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02322671
- Locations
- 🇮🇳
GSK Investigational Site, Hyderabad, India
Antimicrobial Agent for Reducing Bacteria in Aerosols and Oral Cavity
Phase 4
Completed
- Conditions
- Dental Prophylaxis and Implant Surgery
- Interventions
- Drug: Sodium fluoride toothpaste (Aquafresh Mild & Minty)
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT02319668
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT02314143
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis
Phase 3
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 960
- Registration Number
- NCT02311881
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Drug: GSK2982772 solutionDrug: GSK2982772 capsuleDrug: Placebo solutionDrug: Placebo capsule
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 79
- Registration Number
- NCT02302404
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath